LifeMD price target lowered to $10 from $18 at BTIG

BTIG lowered the firm’s price target on LifeMD (LFMD) to $10 from $18 and keeps a Buy rating on the shares. LifeMD’s results reflected pressure on weight management from competitors who are offering lower-cost and potentially lower-quality compounded GLP-1 products, that are under-pricing more established platforms like LifeMD who more closely follow regulatory and quality protocols, the analyst tells investors in a research note. BTIG believes the headwinds and revenue lumpiness are temporary, and growth should reaccelerate in 2026.